A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer



Status:Recruiting
Conditions:Blood Cancer, Lymphoma, Endocrine, Hematology, Leukemia
Therapuetic Areas:Endocrinology, Hematology, Oncology
Healthy:No
Age Range:Any
Updated:10/21/2012
Start Date:June 2010
Contact:Aaron Siek
Email:asiek@pcyc.com
Phone:408-215-3306

Use our guide to learn which trials are right for you!

A Long-term Safety Study of the Pan-histone Deacetylase (HDAC) Inhibitor, PCI-24781, in Subjects With Cancer


The purpose of this study is to determine the long-term (> 6 months) safety of PCI 24781 PO
in subjects with lymphoma.


An open-label, monotherapy, multicenter, extension study open to subjects who have derived
benefit from PCI 24781 PO for at least 6 months and want to continue receiving study drug.

Subjects enrolled in this study will receive PCI-24781 at the schedule and dosage from their
prior protocol. Treatment may be continued as long as there is no evidence of progressive
disease or unacceptable toxicity.

Inclusion Criteria:

1. Men and women with cancer that did not progress while treated with PCI 24781 PO for
at least 6 months and who want to continue receiving study drug

2. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2

3. Agreement to use contraception during the study and for 30 days after the last dose
of study drug if sexually active and able to bear children

4. Willing and able to participate in all required evaluations and procedures in this
study protocol including swallowing capsules without difficulty

5. Ability to understand the purpose and risks of the study and provide signed and dated
informed consent and authorization to use protected health information (in accordance
with national and local subject privacy regulations)

Exclusion Criteria:

1. A life-threatening illness, medical condition or organ system dysfunction which, in
the investigator's opinion, could compromise the subject's safety, interfere with the
absorption or metabolism of oral PCI-24781, or put the study outcomes at undue risk

2. Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias,
congestive heart failure, or myocardial infarction within 6 months of screening, or
any Class 3 or 4 cardiac disease as defined by the New York Heart Association
Functional Classification

3. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or
resection of the stomach or small bowel or ulcerative colitis, symptomatic
inflammatory bowel disease, or partial or complete bowel obstruction

4. Immunotherapy, chemotherapy, radiotherapy, corticosteroids (at dosages equivalent to
prednisone > 20 mg/day) or experimental therapy (other than PCI-24781 PO) within 4
weeks before first dose of study drug

5. Concomitant use of medicines known to cause QT prolongation or torsades de points
(see Appendix 2)

6. Central nervous system involvement by lymphoma

7. Known history of Human Immunodeficiency Virus (HIV) or active infection with
Hepatitis C Virus (HCV) or Hepatitis B Virus (HBV) or any uncontrolled active
systemic infection

8. Creatinine > 1.5 x institutional upper limit of normal (ULN); total bilirubin > 1.5 x
ULN (unless due to Gilbert's disease); and aspartate aminotransferase (AST) or
alanine aminotransferase (ALT) > 2.5 x ULN

9. Lactating or pregnant
We found this trial at
7
sites
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
201 East Huron Street
Chicago, Illinois 60611
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Lafayette, Indiana 47905
?
mi
from
Lafayette, IN
Click here to add this to my saved trials
3322 West End Avenue
Nashville, Tennessee 37203
(615)329-SCRI (7274)
Sarah Cannon Research Institute Sarah Cannon Research Institute (SCRI) is a global strategic research organization...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Emile St
Omaha, Nebraska 68198
(402) 559-4000
Univ of Nebraska Med Ctr A vital enterprise in the nation’s heartland, the University of...
?
mi
from
Omaha, NE
Click here to add this to my saved trials
8303 Dodge Street
Omaha, Nebraska 68114
(402) 354–4000
Nebraska Methodist Hospital Methodist Hospital is a general medical and surgical hospital in Omaha, NE....
?
mi
from
Omaha, NE
Click here to add this to my saved trials
San Fransisco, California 94143
?
mi
from
San Fransisco, CA
Click here to add this to my saved trials